Colorectal Cancer Stage II, Colorectal Cancer Stage III
Conditions
Keywords
ctDNA, Adjuvant chemotherapy, Colorectal Cancer
Brief summary
The purpose of this study was to observe the relationship between ctDNA as a molecular marker of colorectal cancer and the risk of postoperative recurrence.
Detailed description
In this clinical study, ctDNA will be detected in postoperative patients with stage Ⅱ and Ⅲ colorectal cancer to evaluate the correlation between ctDNA and the risk of postoperative recurrence. According to the dynamic changes of ctDNA after adjuvant chemotherapy, the correlation between ctDNA and postoperative DFS will be compared, and the feasibility of ctDNA as a molecular marker to evaluate the risk of postoperative recurrence of colorectal cancer will be investigated.
Interventions
PROCEDUREChemotherapy time
6 months of chemotherapy
Sponsors
Fujian Cancer Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* 1\. Patients with colorectal cancer diagnosed pathologically as stage Ⅱ and stage Ⅲ. * 2\. The patient underwent radical surgical treatment. * 3\. The patient has the results of genetic genetic testing for gastrointestinal tumors, including the genetic mutation status of MMR genes and related genes (MLH1, MSH2, MSH6, PMS2, MLH3, EPCAM). * 4\. The patient understands and is willing to sign a written informed consent document. * 5\. During the treatment process, the patient can cooperate to provide samples of each node. * 6\. The patient can provide corresponding clinical materials, including but not limited to case diagnosis, imaging evaluation, and serum protein marker test results.
Exclusion criteria
* 1\. The patient cannot provide a complete and qualified specimen. * 2\. The patient has other primary malignant tumors or serious medical illnesses. * 3\. The patient cannot cooperate with the follow-up. * 4\. Conditions that other researchers deemed inappropriate for continuing to participate in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ctDNA status | Two weeks | Detect postoperative tissue ctDNA status |
| ctDNA dynamic detection | 6 months | ctDNA dynamic monitoring during postoperative adjuvant chemotherapy |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Imaging examination | 6 months | Imaging examination during postoperative adjuvant chemotherapy |
| Tumor Marker examination | 6 months | Tumor marker examination during postoperative adjuvant chemotherapy |
Contacts
Primary ContactXiaojie Wang
Outcome results
None listed